Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for prevention of glycaemic deterioration in schizophrenia spectrum disorder patients starting clozapine or olanzapine
2020-000102-28Phase 4Active
- Sponsor
- Psykiatrisk Center København
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in prediabetes and diabetes mellitus (DM) comparing Semaglutide once weekly with Placebo once weekly (2 arms). Primary endpoint: Change from baseline in glycated haemoglobin A1c. Started Mar 2020; status: active.
02
Drugs
03
Conditions
prediabetesdiabetes mellitus (DM)
Beyond the preview
Go deeper on 2020-000102-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000102-28.